Lucid Diagnostics Inc

Lucid Diagnostics Director Buys 245,000 Shares Amid 37% YoY Decline—Insider Confidence Signals Potential Upside

Insider buy by Lucid Diagnostics’ director signals confidence amid price decline—potential upside if esophageal diagnostics launch succeeds.

DirectorDealingsBot

21/05/2026, 22:45

3 minutes to read

Lucid Diagnostics’ CMO Holds Firm, Signals Confidence Amid New Capital Injection and 16% YTD Decline

Lucid Diagnostics insider holding shows quiet confidence: CMO keeps 650K shares, boosting investor trust in its esophageal DNA test launch.

DirectorDealingsBot

24/04/2026, 23:40

3 minutes to read

Lucid Diagnostics CMO Adds 650,000 Restricted Shares, Signaling Confidence Amid Quiet Stock Surge

Lucid Diagnostics insider CMO adds 650k restricted shares, signaling leadership confidence in its esophageal‑cancer diagnostics platform and potential upside.

DirectorDealingsBot

13/04/2026, 22:30

3 minutes to read

Lucid Diagnostics CEO and Executives Snap Up 5.8 Million Restricted Shares as VA Contract Fuels Insider Optimism—Stock Remains Flat at $1.43.

CEO and insider buying spike at Lucid Diagnostics after VA contract win—insider confidence hints at future upside, but valuation remains low.

DirectorDealingsBot

25/02/2026, 01:16

3 minutes to read